Lonza Small Molecules provides advanced molecular synthesis CDMO services from early development to commercial manufacturing.
Currently Offered
Lonza Small Molecules provides comprehensive and innovative advanced molecular synthesis services, from early-stage development to commercial manufacturing. Its expertise covers APIs, intermediates, and drug products, ensuring quality and efficiency throughout a project, with specialized infrastructure for API drug substance, specialty and enhanced drug products including bioavailability enhancement and low-dose highly potent applications, and regulatory affairs CMC services supporting accelerated pathways.
The Small Molecules business is part of Lonza's advanced synthesis division, built on collaboration and more than 125 years of expertise, offering integrated solutions across Lonza platforms and modalities with world-class global facilities as a single CDMO partner.
